Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Personlig Gentagen Transkraniel Magnetisk Stimulering (PrTMS) til Behandling af Posttraumatisk Stressforstyrrelse (PTSD)

10. november 2026 opdateret af: Kaloyan Tanev, MD, Massachusetts General Hospital

Personlig Repetitiv Transkraniel Magnetstimulering (PrTMS) til behandling af Posttraumatisk Stresslidelse (PTSD)

This study is testing a personalized form of brain stimulation called PrTMS as a treatment for post-traumatic stress disorder (PTSD) in military service members and veterans. Unlike standard approaches, this treatment uses a simple brainwave test (EEG) to tailor the therapy to each individual. Participants will be randomly assigned to receive either active treatment or a comparison (sham) treatment over 6 weeks. Researchers will track changes in PTSD symptoms, mood, sleep, and overall well-being, including using wearable devices to measure things like sleep and heart rate. The goal is to see whether this personalized approach can provide greater and longer-lasting relief for individuals living with PTSD.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study is a randomized, double-blind, sham-controlled trial evaluating a personalized approach to repetitive transcranial magnetic stimulation (PrTMS) for the treatment of post-traumatic stress disorder (PTSD) in military service members and veterans. PrTMS integrates spectral electroencephalography (sEEG) with neurocognitive assessments to individualize stimulation parameters, including frequency and intensity, and to allow for dynamic adjustment over the course of treatment based on each participant's evolving neurophysiological profile. Participants will undergo a 6-week treatment protocol (5 sessions per week), followed by longitudinal assessments over 6 months to evaluate durability of response. Multimodal outcomes will include clinician-administered and self-report measures of PTSD, mood, anxiety, and sleep, as well as physiologic and behavioral data collected via wearable devices. This study is designed to determine whether EEG-guided, precision neuromodulation improves clinical outcomes compared to standard, non-personalized stimulation approaches and to inform the development of individualized treatment strategies in PTSD.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Massachusetts
      • Charlestown, Massachusetts, Forenede Stater, 02129
        • Home Base
        • Kontakt:
        • Ledende efterforsker:
          • Sofia E Matta, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Reserve or former member of the military (veteran status)
  • Age 18 years or older
  • Primary diagnosis of post-traumatic stress disorder (PTSD) confirmed by the - Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
  • Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) score ≥ 33, indicating clinically significant PTSD symptoms
  • Proficient in English (spoken and written) to ensure understanding of study procedures and informed consent

Exclusion Criteria:

  • History of open-skull traumatic brain injury
  • Clinically significant seizure disorder or history of manic episodes
  • Neurological conditions associated with increased risk (e.g., increased intracranial pressure, brain lesions, stroke, cerebral aneurysm)
  • Electroencephalogram (EEG) abnormalities suggesting elevated seizure risk
  • Repetitive transcranial magnetic stimulation (rTMS) within 3 months prior to screening
  • Current use of antipsychotic or anticonvulsant medications
  • Presence of intracranial implants or non-removable metal in or near the head (excluding the mouth)
  • Clinically significant or unstable medical conditions, including active suicidal ideation
  • Uncontrolled medical illness (e.g., thyroid, hepatic, cardiac, pulmonary, or renal disease)
  • Initiation of PTSD-specific treatment within the past 4 weeks (participants on a stable regimen may be eligible)
  • Pregnancy (for women of childbearing potential)
  • Any condition that, in the opinion of the investigator, may interfere with study participation or completion

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Active PrTMS (EEG-Guided rTMS)

Participants receive personalized, EEG-guided repetitive transcranial magnetic stimulation (PrTMS) administered 5 days per week for 6 weeks, with stimulation parameters individualized and adjusted over time based on serial sEEG and neurocognitive assessments.

Personalized repetitive transcranial magnetic stimulation (PrTMS) is delivered using the Neurocare Apollo TMS Therapy System for 30 minutes per session, 5 days per week, over 6 weeks. Stimulation parameters (frequency 8-13 Hz and intensity typically 50-60% of motor threshold) are individualized based on baseline and serial spectral EEG (sEEG) assessments, with adjustments made throughout treatment to optimize response.

Sham-komparator: Sham PrTMS

Participants receive sham repetitive transcranial magnetic stimulation (rTMS) administered 5 days per week for 6 weeks using a sham coil that mimics the sound and sensation of active treatment without delivering a therapeutic magnetic field.

Sham stimulation will be delivered using the same Neurocare Apollo TMS Therapy System as the active intervention, with identical treatment schedule (5 days per week for 6 weeks; 30 minutes per session). A sham coil identical in appearance to the active coil will be used, which does not generate a therapeutic magnetic field. To mimic the sensory experience of active treatment, the sham procedure will produce similar auditory clicking and will include a surface electrical stimulation (TENS) applied to the forehead to replicate scalp sensations and mild muscle contraction. This approach is designed to maintain blinding while delivering no active neuromodulatory effect.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Tidsramme: At baseline and the end of treatment at Week 6.

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a structured interview and gold standard for diagnosing and assessing PTSD in clinical and research settings. It assesses current or lifetime PTSD based on DSM-5 criteria and measures symptom severity across the 20 PTSD symptoms, including the dissociative subtype, in relation to a single index traumatic event. Total severity scores range from 0 to 80, with higher scores indicating worse PTSD symptom severity.

At baseline and the end of treatment at Week 6.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5)
Tidsramme: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Post-Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses PTSD symptom presence and severity across DSM-5 symptom clusters, including re-experiencing, avoidance, negative alterations in cognition and mood, and arousal. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Generalized Anxiety Disorder-7 (GAD-7)
Tidsramme: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report scale used to assess the severity of generalized anxiety symptoms and to screen for anxiety over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure used to screen, diagnose, monitor, and assess the severity of depression. Total scores range from 0 to 27, with higher scores indicating greater depression severity.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Tinnitus Functional Index (TFI)
Tidsramme: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Tinnitus Functional Index (TFI) is a 25-item self-report questionnaire designed to measure the severity, negative impact, and treatment-related changes of tinnitus on a person's daily life over the past week. Total scores range from 0 to 100, with higher scores indicating greater tinnitus severity and functional impact.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
TMS Tolerability Worksheet (TTW)
Tidsramme: At baseline and weekly during Weeks 1-6.

The TMS Tolerability Worksheet (TTW) is a clinician-administered tool used to document session-related side effects and adverse events associated with transcranial magnetic stimulation (TMS), including symptoms such as headache, neck pain, discomfort at the stimulation site, and hearing changes, with severity categorized as none, mild, moderate, or severe.

At baseline and weekly during Weeks 1-6.
Pittsburgh Sleep Quality Index Addendum (PSQI-A)
Tidsramme: At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.

The Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) is a self-report measure that assesses disruptive nocturnal behaviors associated with PTSD, including nightmares, panic, hot flashes, and acting out dreams. Total scores range from 0 to 21, with higher scores indicating greater severity of disruptive nocturnal behaviors.

At baseline, and weekly during Weeks 1-6, and at Week 10, Week 22, and Week 34.
Total Sleep Time (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Total sleep time, measured in hours per night using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Sleep Efficiency (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Sleep efficiency, expressed as a percentage (0-100%) representing the ratio of time spent asleep relative to the total time in bed, using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Sleep Latency (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Sleep latency, measured in minutes, defined as the time from the start of the sleep period to sleep onset, as recorded by the Oura Ring wearable device. Typical values range from approximately 0 to 60 minutes.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
REM Sleep Duration (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of rapid eye movement (REM) sleep, measured in minutes using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
REM Sleep Percentage (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

REM sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Light Sleep Duration (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of light sleep, measured in minutes using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Light Sleep Percentage (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Light sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Deep Sleep Duration (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of deep (slow-wave) sleep, measured in minutes using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Deep Sleep Percentage (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Deep (slow-wave) sleep expressed as a percentage of total sleep time, measured using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Resting Heart Rate (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Resting heart rate, measured in beats per minute (bpm) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Heart Rate Variability (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Heart rate variability (HRV), measured in milliseconds (ms) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Body Temperature (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Nightly body temperature deviation from baseline, measured in degrees Fahrenheit (°F) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Daily Step Count (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Daily step count, measured as the number of steps per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Active Energy Expenditure (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Active energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Total Energy Expenditure (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Total energy expenditure, measured in kilocalories per day (kcal/day) using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Sedentary Activity Duration (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of sedentary activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Light Activity Duration (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of light physical activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Moderate Activity Duration (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of moderate physical activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.
Vigorous Activity Duration (Oura Ring)
Tidsramme: Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Duration of vigorous physical activity, measured in minutes per day using the Oura Ring wearable device.

Continuously from enrollment through Week 6, and at follow-up at Week 10, Week 22, and Week 34.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Kaloyan S Tanev, MD, Massachusetts General Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juni 2027

Primær færdiggørelse (Anslået)

31. maj 2029

Studieafslutning (Anslået)

31. december 2029

Datoer for studieregistrering

Først indsendt

24. marts 2026

Først indsendt, der opfyldte QC-kriterier

10. april 2026

Først opslået (Faktiske)

13. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2025P003206

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared. Only de-identified, aggregate data may be shared with collaborators, including the United States Air Force Research Laboratory (USAFRL), under a data sharing agreement.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .